Loading
Loading…
Loading…
| # | Company | Offered Item | Amount | Rank | Status |
|---|---|---|---|---|---|
| 1 | L1₹32.3 LQualified Make: Branded
Model: Vabysmo
Title: INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML S 2 GROUND FLOOR OKHLA INDUSTRIAL AREA PHASE II NEW DELHI DELHI 110020 | SOUTH EAST DELHI | DELHI | 110020 | Make: Branded
Model: Vabysmo
Title: INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML | L1 | Qualified MII | |
| 2 | L2₹42 L+₹9.7 L (30.1%)Qualified Make: NA
Model: FARICIMAB
Title: INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML | Make: NA
Model: FARICIMAB
Title: INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML | L2 | Qualified MII |
Tender Value
Refer Docs
EMD Value
₹1.1 L
Closing Date
20 Dec 2025, 1:00 pmClosed
INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML
8563759
GEM/2025/B/6869393
Two Packet Bid
INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML
30 days
LUCKNOW
Total value wise evaluation
PRODUCT_CUSTOM
7 documents required · 7 mandatory
3 yrs
₹16 L
₹1.3 Cr
10%
₹1.1 L
29 Nov 2025
29 Nov 2025
20 Dec 2025
INTRAVITREAL INJECTION FARICIMAB 6MG PER 0 POINT 05 ML 120MG PER ML
intravitreal injection Faricimab 6mg/0.5ml (120mg/ml)
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_8563759.pdf
GEM_BID
dpp_20251104_155243_2025-11-04-13-24-34_9536d6f4fa27001babf8ad287aa4670f.pdf
SPECIFICATION
BBQR_042d6b6b-f204-4b96-b7e61764399413924_MSPCmemb2.pdf
OTHER
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .